What is it about?
Diffuse large B-cell lymphoma, or DLBCL, is a highly diverse disease, with differing forms and different prognoses. This paper uses a Q&A format to explore some of the current questions relevant to the management of the disease, with a view toward future options for treatment.
Featured Image
Read the Original
This page is a summary of: The rationale for combination therapy in patients with aggressive B-cell non-Hodgkin lymphoma: ten questions, Future Oncology, October 2018, Future Medicine,
DOI: 10.2217/fon-2018-0388.
You can read the full text:
Contributors
The following have contributed to this page
